Plain-English translation of NCT06898385 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called for people with advanced pancreatic cancer. This medication is designed to work with your own immune system — doctors remove some of your white blood cells, train them in a laboratory to recognize and attack cancer cells with a specific genetic change (called KRAS G12V), and then give them back to you. The goal is to see if this approach is safe and whether it can help slow or stop your cancer.
Standard chemotherapy treatments for advanced pancreatic cancer don't work for everyone, and many patients need new options. This medication represents a different approach — using your body's own immune cells as a targeted weapon — which researchers hope could help patients whose cancer has stopped responding to traditional drugs.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first have screening tests including blood work, imaging scans, and genetic testing to confirm you qualify. Next, doctors will collect some of your white blood cells through a procedure similar to donating blood plasma. Your cells are then sent to a laboratory for about 2–4 weeks to be trained to fight your cancer. Meanwhile, you may receive mild chemotherapy to prepare your body. Once the cells are ready, you will receive them back as a single infusion. After that, you will have regular clinic visits and imaging scans for up to 2 years to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China